Skip to main content
LB

Link Biologics

The startup develops a protein biologic that combines anti-inflammatory and tissue-protecting properties for individuals with inflammatory and degenerative disorders. This product aims to enhance the daily activities and quality of life for patients suffering from musculoskeletal and ophthalmological diseases.

London, United KingdomFounded 20215300+ followers
Updated 3 months ago

Funding

$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Inflammatory and tissue-degenerative disorders, such as arthritis and dry eye disease, affect over a billion people worldwide, significantly limiting their daily activities and reducing their quality of life. Current treatments often fail to fully address the underlying inflammation and tissue damage, resulting in a substantial burden on healthcare systems and reduced productivity for sufferers.

Solution

Link Biologics is developing Link_TSG6, a protein biologic based on TSG-6, a naturally occurring human protein with potent anti-inflammatory and tissue-protecting properties. Link_TSG6 reduces inflammation through multiple mechanisms, limits tissue injury, and promotes tissue repair without fibrosis. This platform technology is applicable to a broad range of diseases, with initial development focused on Dry Eye Disease (DED) and Osteoarthritis (OA). By targeting the underlying causes of inflammation and tissue degeneration, Link_TSG6 aims to set a new standard of care for individuals with these debilitating conditions.

Target Audience

The primary target audience includes individuals suffering from inflammatory and tissue-degenerative conditions, such as Dry Eye Disease and Osteoarthritis, as well as healthcare providers seeking novel therapeutic options.

Features

  • Utilizes recombinant human full-length TSG-6 protein (rhTSG-6)
  • Exhibits both anti-inflammatory and tissue-protective properties
  • Promotes tissue repair and reduces fibrosis
  • Targets multiple inflammatory pathways
  • Applicable to a range of inflammatory and degenerative diseases
  • Initial focus on Dry Eye Disease (DED) and Osteoarthritis (OA)
This profile is AI-generated and may contain inaccuracies.